Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2008 by Eastern Cooperative Oncology Group.
Recruitment status was Active, not recruiting

Sponsor:

Collaborator:

National Cancer Institute (NCI)

Information provided by:

Eastern Cooperative Oncology Group

ClinicalTrials.gov Identifier:

NCT00075946

First received: January 12, 2004

Last updated: March 8, 2012

Last verified: October 2008

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	April 2012 (Final data collection date for primary outcome measure)

Publications:

Kahl BS, Williams ME, Hong F, et al.: Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: rituximab extended schedule or re-treatment trial (RESORT) . [Abstract] Blood 110 (11): A-3420, 2007.

To Top